Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) – Equities researchers at Roth Capital issued their Q1 2016 earnings per share estimates for shares of Catalyst Pharmaceutical Partners in a research note issued to investors on Tuesday, according to Zacks Investment Research. Roth Capital analyst S. Henry forecasts that the brokerage will post earnings per share of ($0.06) for the quarter. Roth Capital currently has a “Buy” rating and a $3.25 price objective on the stock. The consensus estimate for Catalyst Pharmaceutical Partners’ Q1 2016 earnings is ($0.07) per share. Roth Capital also issued estimates for Catalyst Pharmaceutical Partners’ Q4 2016 earnings at ($0.10) EPS and FY2020 earnings at $0.45 EPS.
A number of other research analysts also recently weighed in on the company. Zacks Investment Research downgraded Catalyst Pharmaceutical Partners from a “hold” rating to a “sell” rating in a research note on Friday, February 26th. Piper Jaffray reissued a “buy” rating and issued a $6.00 price objective (down from $10.00) on shares of Catalyst Pharmaceutical Partners in a research note on Wednesday, February 17th. Finally, SunTrust reissued a “buy” rating and issued a $6.00 price objective (down from $7.00) on shares of Catalyst Pharmaceutical Partners in a research note on Saturday, February 20th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $6.50.
Shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) traded up 0.80% during midday trading on Wednesday, reaching $1.26. The company’s stock had a trading volume of 279,910 shares. Catalyst Pharmaceutical Partners has a 52-week low of $0.93 and a 52-week high of $5.80. The stock has a 50 day moving average price of $1.33 and a 200-day moving average price of $2.48. The company’s market capitalization is $104.36 million.
In other Catalyst Pharmaceutical Partners news, CEO Patrick J. Mcenany purchased 25,000 shares of the company’s stock in a transaction on Monday, December 28th. The shares were bought at an average cost of $2.39 per share, with a total value of $59,750.00. Following the transaction, the chief executive officer now directly owns 4,237,809 shares in the company, valued at approximately $10,128,363.51. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. Firdapse is used for the treatments of lambert-eaton myasthenic syndrome (NASDAQ:CPRX) and congenital myasthenic syndromes (CMS).
Get a free copy of the Zacks research report on Catalyst Pharmaceutical Partners (CPRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
